<DOC>
	<DOCNO>NCT01037556</DOCNO>
	<brief_summary>The current understanding PR104 justify evaluation PR104 subject relapsed/refractory AML ALL . These include : - Hypoxia . Leukemic bone marrow likely demonstrate level hypoxia sufficient activate PR104 active metabolite PR104H PR104M . - Myelotoxicity primary toxicity MTD . In prior clinical study subject solid tumor PR104 demonstrate myelotoxicity primary toxicity . This observation suggest PR104 exert similar effect leukemic cell . - AKR1C3 . AML report exhibit high level AKR1C3 lead selective activation PR104 within hypoxic oxic leukemic cell . - Preclinical data . PR104 demonstrate impressive activity initial study use primary human ALL mouse model . The initial dose find phase study provide estimate activity toxicity PR104 subject refractory/relapsed AML , determine optimal individualize dose give subject base his/her covariates ( prior CR duration , prior number salvage therapy , age ) . Once potentially beneficial dose determine , expand cohort subject AML ALL receive PR104 uniform dose . This information prove valuable defining future clinical development PR104 , determine PR104 sufficient activity acceptable safety AML warrant future phase II phase III study indication . Primary objective - Determine toxicity recommend dose PR104 administer IV subject relapsed/refractory AML ALL . Secondary objectives - Evaluate pharmacokinetics ( PK ) PR104 series PR104 metabolites - Evaluate anti-tumor effect PR104 - Evaluate expression AKR1C3 bone marrow leukemic cell - Evaluate potential biomarkers hypoxia</brief_summary>
	<brief_title>PR104 Treating Patients With Refractory/Relapsed Acute Leukemia</brief_title>
	<detailed_description>A single arm study define recommend dose PR104 subpopulation patient population . Following informed consent , subject undergo baseline evaluation history , physical exam , blood work , disease assessment . Subjects assign dose PR104 base Bayesian model maintain Statistical department MD Anderson Cancer Center . The model updated toxicity efficacy data generate subject . New subject receive currently predict best dose respective subset base prior treatment , age duration prior response . PR104 administer initially induction therapy 3 cycle . Response assess around day 42 ( +/- 2 day ) study . Subjects obtain CR CRp receive consolidation therapy 4 additional cycle . Subjects evaluate week induction phase study . During consolidation phase study , subject evaluate Day 1 cycle clinically indicate . Subjects clinically significant progression remove study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>Signed informed consent Age 18 year Histologically diagnose acute myeloid leukemia ( AML ) acute lymphocytic leukemia ( ALL ) WHO classification Refractory relapse disease ( require least 5 % leukemic blast bone marrow , regardless presence feature new recurrent dysplastic change extramedullary disease ) accord follow definition : AML Relapsed ( define ≥5 % leukemic blast bone marrow ) receive 2 prior induction regimen , ( i.e. , first second relapse ) ; Refractory ( define ≥5 % leukemic blast bone marrow ) 1 prior induction regimen ( defined failure achieve CR CRp follow induction therapy ) , ( i.e. , 1 induction failure ) . ALL Relapsed/refractory ( define ≥5 % leukemic blast bone marrow ) receive 1 prior induction regimen , ( i.e. , number relapse ) ECOG performance status 02 At least 2 week administration prior antileukemia therapy unless subject progress receiving target therapy continuous dose schedule No remain clinically significant toxicity prior chemotherapy grade 2 great Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must willing use acceptable contraceptive method ( abstinence , oral contraceptive double barrier device ) duration study 30 day follow last dose study drug , must negative urine serum pregnancy test within 2 week prior begin treatment trial Sexually active men must willing use acceptable contraceptive method duration time study 30 day follow last dose study drug Clinical laboratory value within follow range unless consider due leukemic organ involvement : Serum creatinine 2.0 mg/dl ; Total bilirubin 1.5x upper limit normal unless consider due Gilbert 's syndrome ; Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) 3x upper limit normal Willingness provide least one prePR104 leukemia sample ( e.g. , bone marrow peripheral blood ) analysis AKR1C3 . Pregnant nursing subject Uncontrolled intercurrent illness include , limited uncontrolled infection , symptomatic congestive heart failure , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Active heart disease include myocardial infarction within previous 3 month , symptomatic coronary artery disease , arrhythmias control medication , uncontrolled congestive heart failure Another active concomitant malignancy likely effect primary secondary outcome measure current study Subjects receive standard investigational treatment hematologic malignancy ( hydroxyurea ) . Subjects CNS leukemia eligible may receive concurrent standard intrathecal chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Refractory AML</keyword>
	<keyword>Relapsed AML</keyword>
	<keyword>Refractory Acute Myeloid Leukemia</keyword>
	<keyword>Relapsed Acute Myeloid Leukemia</keyword>
	<keyword>Refractory Acute Myelogenous Leukemia</keyword>
	<keyword>Relapsed Acute Myelogenous Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Acute Lymphocytic Leukemia</keyword>
	<keyword>Relapsed Acute Lymphocytic Leukemia</keyword>
	<keyword>Refractory Acute Lymphocytic Leukemia</keyword>
	<keyword>Relapsed ALL</keyword>
	<keyword>Refractory ALL</keyword>
</DOC>